Pancreas
J Clin Oncol. 2023;41(7):1359–69
Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211)
Purpose: Patients with advanced pancreatic neuroendocrine tumors (NETs) have few treatment options that yield objective responses. Retrospective and small prospective studies suggest that capecitabine and temozolomide are associated with high response rates (RRs) and long progression-free survival (PFS). Patients and methods: E2211 was a multicenter, randomized, phase 2 trial comparing temozolomide versus capecitabine/temozolomide in patients with advanced low-grade or intermediate-grade pancreatic NETs. Key eligibility criteria included progression within the preceding 12 months and no prior temozolomide, dimethyl-triazeno-imidazole-carboxamide or dacarbazine, capecitabine or fluorouracil. The primary end point was PFS; secondary end points were overall survival (OS), RR, safety, and methylguanine methyltransferase (MGMT) by immunohistochemistry and promoter methylation.
Results: A total of 144 patients were enrolled between April 2013 and March 2016 to temozolomide (n = 72) or capecitabine and temozolomide (n = 72); the primary analysis population included 133 eligible patients. At the scheduled interim analysis in January 2018, the median PFS was 14.4 months for temozolomide versus 22.7 months for capecitabine/temozolomide (hazard ratio [HR] = 0.58), which was sufficient to reject the null hypothesis for the primary end point (stratified log-rank p = 0.022). In the final analysis (May 2021), the median OS was 53.8 months for temozolomide and 58.7 months for capecitabine/temozolomide (HR = 0.82, p = 0.42). MGMT deficiency was associated with response.
Conclusion: The combination of capecitabine/temozolomide was associated with a significant improvement in progression-free survival (PFS) compared with temozolomide alone in patients with advanced pancreatic neuroendocrine tumors (NETs). The median PFS and response rate observed with capecitabine/temozolomide are the highest reported in a randomized study for pancreatic NETs. Methylguanine methyltransferase (MGMT) deficiency was associated with response, and although routine MGMT testing is not recommended, it can be considered for select patients in need of objective response.